Acute Lymphoblastic Leukemia (ALL)

The earliest signs of ALL typically reflect bone marrow failure rather than a single specific symptom. Patients commonly experience persistent fatigue and pallor (from anaemia), unexplained bruising or bleeding (from low platelets), and recurrent or unusual infections (from neutropenia). Children may report bone pain, particularly in the legs and back, from blast infiltration of the periosteum. Swollen lymph nodes, fever, and abdominal discomfort from an enlarged spleen or liver are also common. Because these symptoms develop rapidly — often over days to weeks — any unexplained combination of these features should prompt urgent blood count testing.

ALL in children, particularly those aged 2–10 with standard-risk features, is one of the more treatable haematological malignancies with modern paediatric protocols. Adult ALL is a distinctly different clinical challenge — older patients tolerate intensive chemotherapy less well, high-risk molecular features (Ph+ ALL, Ph-like ALL) are more prevalent, and outcomes are considerably less favourable as age increases. Adults under 40 benefit from paediatric-inspired regimens, while older adults may be better suited to less intensive approaches combining TKIs with immunotherapy (blinatumomab) rather than traditional multi-agent chemotherapy.

Ph+ ALL (Philadelphia chromosome-positive ALL) is defined by the BCR-ABL1 fusion gene, found in approximately 25% of adult B-ALL. This fusion drives leukaemic cell proliferation via an overactive ABL kinase. Historically, Ph+ ALL had the worst prognosis of any B-ALL subgroup. The addition of tyrosine kinase inhibitors (TKIs) such as dasatinib, imatinib, or ponatinib to standard chemotherapy — or, increasingly, to immunotherapy-based regimens — has transformed outcomes in this subtype. All patients with B-ALL should have BCR-ABL1 testing at diagnosis so TKI therapy can be started immediately if positive.

Minimal Residual Disease (MRD) refers to tiny numbers of leukaemia cells that remain in the bone marrow or blood after treatment has produced a morphological complete remission. MRD is measured by highly sensitive techniques — flow cytometry, PCR, or next-generation sequencing — that can detect one leukaemia cell among ten thousand or even one million normal cells. MRD status is the strongest predictor of long-term outcome in ALL: patients who achieve deep MRD negativity after induction and consolidation have a significantly lower relapse risk, while those who remain MRD positive are at high risk of relapse and may need treatment intensification, immunotherapy addition, or stem cell transplantation.

CAR-T (Chimeric Antigen Receptor T-cell) therapy involves genetically engineering a patient's own T cells to express a receptor that recognises and kills CD19-positive leukaemia cells. Tisagenlecleucel (Kymriah) is approved for paediatric and young adult patients with relapsed or refractory B-ALL who have failed two or more prior lines of therapy. CAR-T cell therapy has produced remarkable responses — including deep MRD negativity — in patients with previously untreatable disease. CancerFax can help patients and families understand eligibility criteria, navigate the leukapheresis and manufacturing process, and access CAR-T programmes at specialist centres in India and internationally.

Relapsed ALL remains a major clinical challenge, particularly when relapse occurs within 18 months of completing initial therapy or after allogeneic stem cell transplantation. The approach to relapsed ALL depends on timing, disease characteristics, prior therapies, and patient fitness. Key options include blinatumomab, inotuzumab ozogamicin, conventional salvage chemotherapy, TKI modification in Ph+ ALL, and CD19-directed CAR-T cell therapy as a bridge to transplant in eligible patients. Enrolment in clinical trials should be actively explored at relapse. A specialist second opinion at a high-volume ALL centre is essential before committing to salvage therapy.

ALL treatment is one of the longest among all haematological malignancies. Induction typically lasts 4–6 weeks. Consolidation/intensification courses are delivered over approximately 6–12 months. Maintenance therapy (oral mercaptopurine and methotrexate) continues for 2–3 years from the start of treatment in patients not proceeding to transplant. The total treatment duration is therefore typically 2–3 years. For Ph+ ALL, TKI therapy is continued for the full duration of treatment and often beyond. Patients proceeding to allogeneic stem cell transplantation follow a different timeline with intensive conditioning, transplant, and then 1–2 years of post-transplant monitoring.

Children treated for ALL, particularly those who received cranial radiation therapy (now largely replaced by intensified chemotherapy in modern protocols), are at risk of neurocognitive late effects including memory, attention, and processing speed difficulties. Other potential late effects include cardiomyopathy from anthracyclines, growth hormone deficiency, early menopause or infertility, avascular necrosis of bone (from steroids), and a small increased risk of secondary malignancies. Long-term survivorship follow-up through a dedicated late effects clinic is recommended for all paediatric ALL survivors to monitor for and manage these sequelae.

Yes — CancerFax provides comprehensive support for ALL patients and their families across all stages of the disease. Our services include structured medical record review and case summarisation for specialist consultation, second opinion coordination with haematologists and ALL specialists at leading centres in India, China, and globally, guidance on eligibility for CAR-T cell therapy and immunotherapy access programmes, and clinical trial navigation for patients with relapsed, refractory, or high-risk ALL. We assist with cross-border treatment logistics including travel, interpretation, and hospital coordination. Share your medical reports or contact our team to explore your options.